Lan Xie is CFO & VP at SCICLONE PHARMACEUTICALS INC (SCLN). They have made 6 open-market trades across 1 company since 2015, most recently 2017-10-13.
CIK 0000880771
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SCLN | 8,000 | $89K |
Shares reported on the most recent Form 4, priced at the 2017-10-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SCLN | SELL | 2017-08-16 | 2017-08-16 | $11.00 | $110K | +0.2% | +0.7% | N/A |
| SCLN | SELL | 2017-06-12 | 2017-06-14 | $10.75 | $11K | +1.4% | +1.4% | +2.3% |
| SCLN | SELL · 10b5-1 | 2017-03-16 | 2017-03-17 | $9.60 | $10K | +1.6% | +0.5% | +13.1% |
| SCLN | SELL | 2016-08-12 | 2016-08-16 | $10.36 | $592K | -1.1% | -3.2% | -2.5% |
| SCLN | SELL | 2016-08-12 | 2016-08-16 | $10.36 | $301K | -1.1% | -3.2% | -2.5% |
| SCLN | SELL | 2015-12-03 | 2015-12-07 | $9.50 | $135K | -15.6% | -5.2% | +12.7% |
| SCLN | SELL | 2015-05-15 | 2015-05-18 | $9.20 | $245K | -15.6% | -3.7% | -3.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.